Related Experiment Video
Updated: Jun 17, 2026

Quantification of Violacein in Chromobacterium violaceum and Its Inhibition by Bioactive Compounds
Published on: August 8, 2025
Inhibition of bacterial disulfide bond formation by the anticoagulant warfarin
Rachel J Dutton1, April Wayman, Jun-Rong Wei
1Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA.
Abstract:
Blood coagulation in humans requires the activity of vitamin K epoxide reductase (VKOR), the target of the anticoagulant warfarin (Coumadin). Bacterial homologs of VKOR were recently found to participate in a pathway leading to disulfide bond formation in secreted proteins of many bacteria. Here we show that the VKOR homolog from the bacterium Mycobacterium tuberculosis, the causative agent of human tuberculosis, is inhibited by warfarin and that warfarin-resistant mutations of mycobacterial VKOR appear in similar locations to mutations found in human patients who require higher doses of warfarin. Deletion of VKOR results in a severe growth defect in mycobacteria, and the growth of M. tuberculosis is inhibited by warfarin. The bacterial VKOR homolog may represent a target for antibiotics and a model for genetic studies of human VKOR. We present a simple assay in Escherichia coli, based on a disulfide-sensitive beta-galactosidase, which can be used to screen for stronger inhibitors of the M. tuberculosis VKOR homolog.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Preparation and Reactions of Thiols
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Bacterial DNA Synthesis
Combined Effects of Drugs: Synergism
Such synergistic combinations...

